Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Übersichtsarbeit

Langwirksame Medikamente zur Behandlung der hyperkinetischen Störungen

1bearbeitete deutsche Version von Banaschewski et al., Long-acting medications for the hyperkinetic disorders; Eur Child Adolesc Psychiatry (2006); mit freundlicher Genehmigung des Springer-Verlags.

Eine systematische Übersicht und europäische Behandlungsleitlinien Teil 1: Übersicht und Empfehlungen

Published Online:March 24, 2008https://doi.org/10.1024/1422-4917.36.2.81

Abstract

Zusammenfassung: Ein Expertengremium aus mehreren europäischen Ländern hat sämtliche verfügbaren veröffentlichten und unveröffentlichten Studienergebnisse zum Einsatz von langwirksamen Medikamenten bei ADHS und hyperkinetischer Störung analysiert und auf dieser Grundlage Empfehlungen zur praktischen Anwendung dieser Arzneimittel entwickelt: Auf der Grundlage der Analyse wurde gefolgert: (1) Langwirksame Präparate sollten zugelassen sein und eingesetzt werden; (2) Sie sollen kurzwirksame Arzneimittel (aus Kostengründen und wegen der höheren Flexibilität der Dosierung) nicht vollständig ersetzen. Individuelle Therapieoptionen sind erforderlich. (3) Sowohl ATX als auch Stimulanzien mit retardierter Freisetzung sollten zur Verfügung stehen. Zusätzlich werden ausführliche Empfehlungen gegeben, nach welchen Kriterien ein spezifisches Präparat für den individuellen Patienten ausgewählt werden sollte.


Long-acting medications for the treatment of hyperkinetic disorders - A systematic review and European treatment guideline. Part 1: Overview and recommendations

Summary: A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder. Based on this analysis detailed recommendations about the use of these drugs in practice have been developed: (1) Long-acting preparations should be licensed and used; (2) They should not completely replace short-acting drugs (which will be the initial treatment for many children in view of cost and the greater flexibility of dosing). Individual clinical choices are necessary. (3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient.

Literatur

  • Adler, L. A. , Spencer, T. J. , Milton, D. R. , Moore, R. J. , Michelson, D. (2005). Longterm, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. Journal of Clinical Psychiatry, 6, 294– 299 First citation in articleCrossref, Google Scholar

  • Anlauf, M. (2006). Beurteilung von Therapien mit der «number needed to treat». Deutsches Ärzteblatt, 48, B2831– B2835 First citation in articleGoogle Scholar

  • Allen, A. J. , Kurlan, R. M. , Gilbert, D. L. , Coffey, B. J. , Linder, S. L. , Lewis, D. W. , Winner, P. K. , Dunn, D. W. , Dure, L. S. , Sallee, F. R. , Milton, D. R. , Mintz, M. I. , Ricardi, R. K. , Erenberg, G. , Layton, L. L. , Feldman, P. D. , Kelsey, D. K. , Spencer, T. J. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941– 1949 First citation in articleCrossref Medline, Google Scholar

  • Bangs, M. E. , Hazell, P. , Danckaerts, M. , Williams, D. , Moore, R. J. , Levine, L. (2006). Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder in children and adolescents (accepted for oral presentation). 159th Annual Meeting of the American Psychiatric Association. Atlanta, GA First citation in articleGoogle Scholar

  • Bangs, M. E. , Tauscher-Wisniewski, S. , Polzer, J. , Zhang, S. , Acharya, N. , Desaiah, D. , Allen, A. J. (2005). Meta-analysis of suicide-related events in atomoxetinetreated patients (Poster). 52nd Annual AACAP Meeting, Toronto First citation in articleGoogle Scholar

  • Biederman, J. , Mick, E. , Faraone, S. V. (2000). Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. American Journal of Psychiatry, 157, 816– 818 First citation in articleCrossref Medline, Google Scholar

  • Biederman, J. , Mick, E. , Surman, C. , Doyle, R. , Hammerness, P. , Harpold, T. , Dunkel, S. , Dougherty, M. , Aleardi, M. , Spencer, T. (2005). A randomized, placebo-controlled trial of oros methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 59, 829– 835 First citation in articleCrossref Medline, Google Scholar

  • Connor, D. F. (2002). Psychopharmacology and aggression. I: a metaanalysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 253– 261 First citation in articleCrossref Medline, Google Scholar

  • Döpfner, M. , Gerber, W. D. , Banaschewski, T. , Breuer, D. , Freisleder, F. J. , Gerber-von Muller, G. , Gunter, M. , Hassler, F. , Ose, C. , Rothenberger, A. , Schmeck, K. , Sinzig, J. , Stadler, C. , Uebel, H. , Lehmkuhl, G. (2004). Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. European Child Adolescent Psychiatry, 13, (Suppl 1) I93– 101 First citation in articleGoogle Scholar

  • Faraone, S. V. , Biederman, J. (2004). Using meta-analysis to draw conclusions about ADHD medication effects. 17th ECNP Congress. Stockholm First citation in articleGoogle Scholar

  • Faraone, S. V. , Biederman, J. , Spencer, T. , Aleardi, M. , META-ANALYSIS CTEOMFAU, (2006a). Comparing the efficacy of medications for ADHD using meta-analysis. Medscape General Medicine, 8, 4– First citation in articleMedline, Google Scholar

  • Faraone, S. V. , Biederman, J. , Mick, E. (2006b). The age dependent decline of attention-deficit/hyperactivity disorder: a meta-analysis of follow-up studies. Psychological Medicine, 36, 159– 165 First citation in articleCrossref Medline, Google Scholar

  • Faraone, S. V. , Biederman, J. , Spencer, T. , Aleardi, M. , Pagano, C. (2003). Using a meta-analysis to draw conclusions about ADHD medication effects (Poster). 156th Annual Meeting of the American Psychiatric Association. San Francisco, California First citation in articleGoogle Scholar

  • Faraone, S. V. , Spencer, T. , Aleardi, M. , Pagano, C. , Biederman, J. (2004). Metaanalysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. Journal of Clinical Psychopharmacology, 24, 24– 29 First citation in articleCrossref Medline, Google Scholar

  • Fischer, M. , Barkley, R. A. , Smallish, L. , Fletcher, K. (2002). Young adult followup of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. Journal of Abnormal Child Psychology, 30, 463– 475 First citation in articleCrossref Medline, Google Scholar

  • Greenhill, L. , Vitiello, B. , Abikoff, H. , Kollins, S. , Wigal, S. , Swanson, J. (2004). Outcome results from the NIMH, multi- site, preschool ADHD treatment study (PATS). 51th Annual MCAP meeting, Washington, DC First citation in articleGoogle Scholar

  • Kaplan, S. , Heiligenstein, J. , West, S. , Busner, J. , Harder, D. , Dittmann, R. , Casat, C. , Wernicke, J. F. (2004). Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. Journal of Attention Disorders, 8, 45– 52 First citation in articleCrossref Medline, Google Scholar

  • Kelsey, D. , Sutton, V. , Lewis, D. , Schuh, K. , Sumner, C. , Quintana, H. (2005). Morning- versus evening-dosed atomoxetine: effects on core ADHD symptoms. 158th Annual Meeting of the American Psychiatric Association. Atlanta, GA First citation in articleGoogle Scholar

  • Kelsey, D. K. , Sumner, C. R. , Casat, C. D. , Coury, D. L. , Quintana, H. , Saylor, K. E. , Sutton, V. K. , Gonzales, J. , Malcolm, S. K. , Schuh, K.J. , Allen, A. J. (2004). Once-daily atomoxetine treatment for children with attention- deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics, 114, e1– e8 First citation in articleCrossref Medline, Google Scholar

  • Kemner, J. E. , Wan, G. J. (2003). Increased persistency with once-daily OROS_Methylphenidate: an analysis of healthcare claims. 16th US Psychiatric & Mental Health Congress, Orlando, FL First citation in articleGoogle Scholar

  • King, S. , Griffin, S. , Hodges, Z. , Weatherly, H. , Asseburg, C. , Richardson, G. , Golder, S. , Taylor, E. , Drummond, M. , Riemsma, R. (2004). Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children (commercial in confidence information removed). produced by the Centre for Reviews and Dissemination (CRD). www.nice.org.uk/pdf/ADHD_assessment_ report.pdf First citation in articleGoogle Scholar

  • Klassen, A. F. , Miller, A. , Fine, S. (2004). Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics, 114, e541– e547 First citation in articleCrossref Medline, Google Scholar

  • Kollins, S. H. , Rush, C. R. , Pazzaglia, P. J. , Ali, J. A. (1998). Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Experimental and Clinical Psychopharmacology, 6, 367– 374 First citation in articleCrossref Medline, Google Scholar

  • Kratochvil, C. J. , Greenhill, L. L. , March, J. S. , Burke, W. J. , Vaughan, B. S. (2004). The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder. CNS Drugs, 18, 957– 966 First citation in articleCrossref Medline, Google Scholar

  • Lage, M. , Hwang, P. (2004). Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. Journal of Child and Adolescent Psychopharmacology, 14, 575– 58 First citation in articleCrossref Medline, Google Scholar

  • Lopez, F. , Silva, R. , Pestreich, L. , Muniz, R. (2003a). Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatric Drugs, 5, 545– 555 First citation in articleCrossref Medline, Google Scholar

  • Marchetti, A. , Magar, R. , Lau, H. , Murphy, E. L. , Jensen, P. S. , Conners, C. K. , Findling, R. , Wineburg, E. , Carotenuto, I. , Einarson, T. R. , Iskedjian, M. (2001). Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clinical Therapeutics, 23, 1904– 1921 First citation in articleCrossref Medline, Google Scholar

  • McCabe, S. E. , Teter, C. J. , Boyd, C. J. , Knight, J. R. , Wechsler, H. (2005). Non-medical use of prescription opioids among U.S. college students: prevalence and correlates from a national survey. Addictive Behaviors, 30, 789– 805 First citation in articleCrossref Medline, Google Scholar

  • McGough, J. J. , Biederman, J. , Greenhill, L. L. , McCracken, J. T. , Spencer, T. J. , Posner, K. , Wigal, S. , Gornbein, J. , Tulloch, S. , Swanson, J. M. (2003). Pharmacokinetics of SLI381 (ADDERALL XR), an extended- release formulation of Adderall. Journal of the American Academy of Child & Adolescent Psychiatry, 42, 684– 691 First citation in articleCrossref Medline, Google Scholar

  • Michelson, D. (2004). Results from a double-blind study of atomoxetine, OROS methylphenidate, and placebo. Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 20D, p. 49 First citation in articleGoogle Scholar

  • Michelson, D. , Adler, L. , Spencer, T. , Reimherr, F. W. , West, S.A. , Allen, A. J. , Kelsey, D. , Wernicke, J. , Dietrich, A. , Milton, D. (2003). Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry, 53, 112– 120 First citation in articleCrossref Medline, Google Scholar

  • MTA Cooperative Group, (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. Archives of General Psychiatry, 56, 1073– 1086 First citation in articleCrossref Medline, Google Scholar

  • Newcorn, J. H. , Spencer, T. J. , Biederman, J. , Milton, D. R. , Michelson, D. (2005). Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 240– 248 First citation in articleCrossref Medline, Google Scholar

  • Palumbo, D. , Spencer, T. , Lynch, J. , Co-Chien, H. , Faraone, S.V (2004). Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. Journal of Child and Adolescent Psychopharmacology, 14, 185– 194 First citation in articleCrossref Medline, Google Scholar

  • Perwien, A. R. , Faries, D. E. , Kratochvil, C. J. , Sumner, C. R. , Kelsey, D. K. , Allen, A. J. (2004). Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics, 25, 264– 271 First citation in articleCrossref Medline, Google Scholar

  • Rasmussen, P. , Gillberg, C. (2000). Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, communitybased study. Journal of the American Academy of Child & Adolescent Psychiatry, 39, 1424– 1431 First citation in articleCrossref Medline, Google Scholar

  • Read, H. A. , Bangs, M. E. , Jin, L. , Zhang, S. , Allen, A. J. (2005). Review of hepatic events associated with atomoxetine treatment in ADHD. 52nd Annual AACAP Meeting. Toronto First citation in articleGoogle Scholar

  • Roessner, V. , Robatzek, M. , Knapp, G. , Banaschewski, T. , Rothenberger, A. (2006). «First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants.». Developmental Medicine & Child Neurology, 48, (7) 616– 621 First citation in articleGoogle Scholar

  • SAMHSA (US Department of Health and Human Services-Substance Abuse & Mental Health Service Administration), (2005). US National Survey on Drug Use and Health 2004. www.oas.samhsa.gov/ p0000016.htm#2k4 First citation in articleGoogle Scholar

  • SIGN (Scottish Intercoligiate Guidelines Networt), (2001). Attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. Vol. 52. Edinburgh First citation in articleGoogle Scholar

  • Simpson, D. , Plosker, G. L. (2004). Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs, 64, 205– 222 First citation in articleCrossref Medline, Google Scholar

  • Sonuga-Barke, E. , Daley, D. , Thompson, M. J. S. (2003). The management of preschool AD/HD; Addressing uncertainties about syndrome validity, diagnostic utility and treatment safety. Expert Review of Neurotherapeutics, 3, 89– 100 First citation in articleCrossref, Google Scholar

  • Sonuga-Barke, E. J. , Auerbach, J. , Campbell, S. B. , Daley, D. , Thompson, M. (2005). Varieties of preschool hyperactivity: multiple pathways from risk to disorder. Developmental Science, 8, 141– 150 First citation in articleCrossref Medline, Google Scholar

  • Spencer, T. , Abikoff, H. , Connor, D. F. , Biederman, J. , Pliszka, S. , Boellner, S. , Read, S. C. , Pratt, R. (2006). The safety and efficacy of mixed amphetamine salts extended release Adderall XR in the Management of oppositional defiant disorder (ODD) with or without comorbid attention deficit hyperactivity disorder (ADHD) in School-age Children and Adolescents. Clin Ther, 28, 402– 418 First citation in articleCrossref Medline, Google Scholar

  • Spencer, T. (2004). Safety and efficacy of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder (ODD). 157th Annual Meeting of the American Psychiatric Association, New York First citation in articleGoogle Scholar

  • Spencer, T. , Biederman, J. , Wilens, T. , Doyle, R. , Surman, C. , Prince, J. , Mick, E. , Aleardi, M. , Herzig, K. , Faraone, S. (2005). A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/ hyperactivity disorder. Biological Psychiatry, 57, 456– 463 First citation in articleCrossref Medline, Google Scholar

  • Sumner, C. , Donnelly, C. , Lopez, F. A. , Sutton, V. , Bakken, R. , Paczkowski, M. , Kelsey, D. (2005). Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. 158th Annual Meeting of the American Psychiatric Association. Atlanta, GA First citation in articleGoogle Scholar

  • Swanson, J. , Greenhill, L. , Pelham, W. , Wilens, T. , Wolraich, M. , Abikoff, H. , Atkins, M. , August, G. , Biederman, J. , Bukstein, O. , Conners, C. K. , Efron, L. , Fiebelkorn, K. , Fried, J. , Hoffman, M. , Lambrecht, L. , Lerner, M. , Leventhal, B. , McBurnett, K. , Morse, E. , Palumbo, D. , Pfiffner, L. , Stein, M. , Wigal, S. B. , Winans, E. (2000). Initiating Concerta TM (Oros_ methylphenidate HCl) qu in children with attention-deficit hyperactivity disorder. Journal of Clinical Research, 3, 59– 76 First citation in articleGoogle Scholar

  • Swanson, J. , Gupta, S. , Lam, A. , Shoulson, I. , Lerner, M. , Modi, N. , Lindemulder, E. , Wigal, S. (2003). Development of a new once-a-day formulation of methylphenidate for the treatment of attentiondeficit/hyperactivity disorder: proof-ofconcept and proof-of-product studies. Archives of General Psychiatry, 60, 204– 211 First citation in articleCrossref Medline, Google Scholar

  • Swanson, J. M. , Wigal, S. B. , Wigal, T. , Sonuga-Barke, E. , Greenhill, L. L. , Biederman, J. , Kollins, S. , Nguyen, A. S. , DeCory, H. H. , Hirshe Dirksen, S. J. , Hatch, S. J. (2004). A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics, 113, e206– e216 First citation in articleCrossref Medline, Google Scholar

  • Taylor, E. , Döpfner, M. , Sergeant, J. , Asherson, P. , Banaschewski, T. , Buitelaar, J. , Coghill, D. , Danckaerts, M. , Rothenberger, A. , Sonuga-Barke, E. , Steinhausen, H. C. , Zuddas, A. (2004). European clinical guidelines for hyperkinetic disorder - first upgrade. European Child and Adolescent Psychiatry, 13, (Suppl 1) I7– 30 First citation in articleCrossref, Google Scholar

  • Tourette Syndrome Study Group, (2002). Treatment of ADHD in children with tics: a randomized controlled trial. Neurology, 58, 527– 536 First citation in articleCrossref Medline, Google Scholar

  • Volkow, N. D. , Fowler, J. S. , Wang, G. J. , Swanson, J. M. (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Molecular Psychiatry, 9, 557– 569 First citation in articleCrossref Medline, Google Scholar

  • Wan, G. J. , Cooper, K. M. (2004). Reduced symptoms of opposition and defiance in children with attention-deficit/hyperactivity disorder treated with methylphenidate. 17th US Psychiatric & Mental Health Congress, 2004, San Diego, CA First citation in articleGoogle Scholar

  • Wigal, S. B. , McGough, J. J. , McCracken, J. T. , Biederman, J. , Spencer, T. J. , Posner, K. L. , Wigal, T. L. , Kollins, S. H. , Clark, T. M. , Mays, D. A. , Zhang, Y. , Tulloch, S. J. (2005). A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. Journal of Attention Disorders, 9, 275– 289 First citation in articleCrossref Medline, Google Scholar

  • Wilens, T. , Gignac, M. , Sweezey, A. , Monuteaux, M. , Biederman, J. (2006). Characteristics of Adolescents and Young Adults with ADHD Who Divert or Misuse their Prescribed Medications. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 408– 414 First citation in articleCrossref Medline, Google Scholar

  • Wilens, T. , McBurnett, K. , Stein, M. , Lerner, M. , Spencer, T. , Wolraich, M. (2005). ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 1015– 1023 First citation in articleCrossref Medline, Google Scholar

  • Wilens, T. E. (2003). Does the medicating ADHD increase or decrease the risk for later substance abuse?. Revista Brasileira de Psiquiatria, 25, 127– 128 First citation in articleCrossref Medline, Google Scholar

  • Wolraich, M. L. , Greenhill, L. L. , Pelham, W. , Swanson, J. , Wilens, T. , Palumbo, D. , Atkins, M. , McBurnett, K. , Bukstein, O. , August, G. (2001). Randomized, controlled trial of oros methylphenidate once a day in children with attention deficit/ hyperactivity disorder. Pediatrics, 108, 883– 892 First citation in articleCrossref Medline, Google Scholar